Loading ACEINTEG price...
Peers are the listed companies in the exchange's own industry group: Trading - Chemicals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Latest quarterIn the quarter to June 2026 (results filed 13 Aug 2026), sales fell 70.5% from a year earlier to Rs 0.1 cr and the loss was Rs 0.2 cr against Rs 0.3 cr a year earlier.
- Reported a loss in FY25 and FY26.
Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.
Over the last 14 results, the share rose on 8 and fell on 6, and moved by 3% or more on 8.
Q1 FY27: results filed 13 Aug 2026. The share went from its close on 12 Aug 2026 to its close on 14 Aug 2026 -3.42%.
Of every Rs 100 of sales in FY26, Rs 300 went on running costs, Rs 13 on depreciation; the year ended in a loss.
Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.
Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.
| Measure | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales. | - | - | -26.7% | -200% |
| Net marginProfit after everything, per Rs 100 of sales. | - | - | -17.4% | -125% |
| ROEProfit as a percentage of shareholders' money (from the March balance sheet). | - | - | -8.8% | -5.7% |
| ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'. | - | 2.0% | -11.8% | -7.1% |
| Debt to equityBorrowings divided by shareholders' money. Lower is safer. | 0.01x | 0.01x | 0.01x | 0.00x |
Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).
At FY26 it owned Rs 17 Cr of assets. Its owners funded 98% of that and borrowings 0%.
From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.
In FY26 the business itself brought in Rs -0 Cr, spent Rs 0 Cr on plant and equipment, and cash fell by Rs 0 Cr over the year.
Full financial year to 2026-03-31, from the company's cash flow statement.
Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| UNIENTER Uniphos Enterprises Limited | 604 cr | - | 0.3x | - | 0.8% | 0.00 | - | -100.0% | 0.58% |
| VINYLINDIA Vinyl Chemicals (India) Limited | 440 cr | 23.6x | 3.4x | 14.4% | 16.8% | 0.00 | 3.1% | -34.1% | 2.91% |
| SRD Shankar Lal Rampal Dye-Chem Limited | 247 cr | 13.4x | 2.0x | 15.0% | 15.6% | 0.21 | 3.9% | +10.9% | 0.13% |
| ACEINTEG Ace Integrated Solutions Limited | 17 cr | - | 1.0x | - | -7.1% | 0.00 | - | -70.5% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Operating margin has gone from -26.7% to -200.0% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.
The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Insider trading data unavailable.
Announcements unavailable.
Backtest an equity strategy on real market data, free - no card needed.
Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.